CASR and cancer: In cancer cells harboring mutant IDH1, SDH, or FH, excess oncometabolites (such as D-2-HG, succinate, or fumarate) accumulate, inhibiting PHD and FIH activity, thereby driving cancer progression and therapy resistance.38